Dewmar International BMC Inc (OTCMKTS:DEWM) has filed documents with the USPTO for the treatment of Post-Traumatic Stress Disorder using cannabinoids. As it is known, Post-Traumatic Stress Disorder is a growing concern in the U.S. that is set to reach epidemic proportions in the imminent future. The latest data reveals that PTSD affects around 7 million Americans. This disease can occur at any age and is generally accompanied by symptoms such as insomnia, substance abuse, depression, anxiety and other anxiety disorders.
Years of war in Iraq and Afghanistan have brought PTSD disorder among military recruits to the immediate attention of the general public. As per the latest data it is expected that more than 30% of all Vietnam veterans suffer from PTSD while 10% of all Gulf War veterans struggle with PTSD. This growing problem also impacts 11% of all veterans of the Afghanistan war and 20% of veterans of Iraqi War. Although PTSD has just got attention, it is a grave issue that can also affect non-military people.
Dr. Donisha Dunn-Lombard of Dewmar’s Medical Advisory Board reported that some people may relate the term post-traumatic stress disorder with combat veterans but essentially PTSD can affect any person who has witnessed or experienced a traumatic event like an assault, car accident or natural disaster. Someone suffering from PTSD can face considerable impairment in their functioning at home, at work, and in personal relationships.
Dewmar is establishing an extensive portfolio of IP linked to CBDs and unique delivery systems of these CBDs to treat people troubled with lung disease, PTSD and Parkinson’s Disease. This technology can be utilized to deliver not just cannabinoids but also numerous adjunct therapies including supplements, prescription medications and vitamins to bypass the conventional digestive tract which removes a majority of the active ingredients, and hence causing a jump and dosing with a higher potential for side-effects.